GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ablynx NV (XBRU:ABLXS) » Definitions » LT-Debt-to-Total-Asset

Ablynx NV (XBRU:ABLXS) LT-Debt-to-Total-Asset : 0.23 (As of Dec. 2017)


View and export this data going back to . Start your Free Trial

What is Ablynx NV LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Ablynx NV's long-term debt to total assests ratio for the quarter that ended in Dec. 2017 was 0.23.

Ablynx NV's long-term debt to total assets ratio declined from Dec. 2016 (0.32) to Dec. 2017 (0.23). It may suggest that Ablynx NV is progressively becoming less dependent on debt to grow their business.


Ablynx NV LT-Debt-to-Total-Asset Historical Data

The historical data trend for Ablynx NV's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ablynx NV LT-Debt-to-Total-Asset Chart

Ablynx NV Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.30 0.32 0.23

Ablynx NV Semi-Annual Data
Dec07 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.26 0.32 - 0.23

Ablynx NV LT-Debt-to-Total-Asset Calculation

Ablynx NV's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2017 is calculated as

LT Debt to Total Assets (A: Dec. 2017 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2017 )/Total Assets (A: Dec. 2017 )
=88.715/389.848
=0.23

Ablynx NV's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2017 is calculated as

LT Debt to Total Assets (Q: Dec. 2017 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2017 )/Total Assets (Q: Dec. 2017 )
=88.715/389.848
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ablynx NV  (XBRU:ABLXS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Ablynx NV LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Ablynx NV's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Ablynx NV (XBRU:ABLXS) Business Description

Traded in Other Exchanges
N/A
Address
Ablynx NV is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. It has 45 proprietary and partnered programs in development in various therapeutic areas including inflammation, hematology, immuno-oncology, oncology and respiratory disease. It has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The company generates revenue from research collaboration agreements and from government grants.

Ablynx NV (XBRU:ABLXS) Headlines

No Headlines